Your Cart is Empty
Estro I-3-C, 60 caps
$ 32.50
| Qty | Discount |
|---|---|
| Buy 3 | 3% Off |
| Buy 5 | 5% Off |
Free Shipping On Orders over $50
Nutritionist Approved
60-Day Return Guarantee
DESCRIPTION
NutriKey Estro I-3-C is a potent blend of naturally occurring compounds that support healthy estrogen metabolism and promote healthy hormonal balance.
This formula includes both Indole-3-Carbinol (I-3-C) and diindolylmethane (DIM), both abundantly found in cruciferous vegetables and promote estrogen detoxification from the body.
Estro I-3-C may:
• Support healthy estrogen metabolism
• Promote healthy hormonal balance
• Promote balanced mood and well-being
INGREDIENTS
Serving Size: 1 capsule
Servings per container:60
Pill Size: #1 Veggie capsule
One Capsule Supplies:
| Ingredient | Amount | Daily Value |
|---|---|---|
| Indole-3-Carbinol | 150 mg | * |
| BioResponse DIM® Complex [starch, diindolylmethane (DIM), vitamin E (as tocophersolan), phosphatidyl choline, silica.] |
50 mg | * |
| * Daily Value (DV) not established. |
Other Ingredients: Hypromellose, microcrystalline cellulose, tricalcium phosphate, vegetable magnesium stearate, silica.
Gluten Free | Dairy Free | Non-GMO | Vegetarian | Vegan
All NutriKey brand supplements are Pharmaceutical Grade and produced in Certified GMP (cGMP) facilities. All NutriKey brand supplements meet or exceed cGMP standards and are third party tested.
*BioResponse DIM® is a proprietary, enhanced bioavailability complex containing diindolylmethane licensed from BioResponse, L.L.C., Boulder, Colorado.
DIRECTIONS
Recommendations: Take one capsule up to three times daily as a dietary supplement, or as directed by your healthcare practitioner.
Caution: Do not use if you are pregnant, nursing, or may become pregnant. If taking medication, consult your healthcare practitioner before use. Harmless changes in urine color may occur while using this product. Keep out of reach of children.
Statements contained herein have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent disease.
References
1. Zeligs, M. A., Brownston, P. K., Sharp, M. E., Westerling, K. C., Wilson, S. M., & Johs, S. M. (2005). Managing cyclical mastalgia with absorbable diindolylmethane: A randomized, placebo-controlled trial. Journal of the American Nutraceutical Association, 8(1), 5-15.
2. Zeligs, M. A., Fulfs, J. C., Peterson, R., Wilson, S. M., McIntyre, L., Sepkovic, D. W., & Bradlow, H. L. (2003). In vivo, uterine-protective activity of absorption-enhanced diindolylmethane: Animal and preliminary human use in combination with Tamoxi-fen. Proceedings of the American Association of Cancer Research, 44, 1268.
3. Zeligs, M. A., Sepkovic, D. W., Manrique, C., Macsalka, M., Williams, D. E., & Bradlow, H. L. (2002). Absorption-enhanced 3,3’-diindolylmethane: Human use in HPV-related, benign and pre-cancerous conditions. Proceedings of the American Association of Cancer Research, 43, 3198.
4. Teas, J., Cunningham, J. E., Fowke, J. H., Nitcheva, D., Kanwat, C. P., Boulware, R. J., Sepkovic, D. W., Hurley, T. G., & Hebert, J. R. (2005). Urinary estrogen metabolites, prostate specific antigen, and body mass index among African-American men in South Carolina. Cancer Detection and Prevention, 29(6), 494-500.
5. Michnovicz, J. J., Adlercreutz, H., & Bradlow, H. L. (1997). Changes in levels of urinary estrogen metabolites after oral indole-3-carbinol treatment in humans. Journal of the National Cancer Institute, 89(10), 718-723.
6. Chen, I., McDougal, A., Wang, F., & Safe, S. (1998). Aryl hydrocarbon receptor-mediated antiestrogenic and antitumorigenic activity of diindolylmethane. Carcinogenesis, 19(9), 1631-1639.
7. Aggarwal, B. B., & Ichikawa, H. (2005). Molecular targets and anticancer potential of indole-3-carbinol and its derivatives. Cell Cycle, 4(9), 1201-1215.
8. Leong, H., Riby, J. E., Firestone, G. L., & Bjeldanes, L. F. (2004). Potent ligand-independent estrogen receptor activation by 3,3’-diindolylmethane is mediated by cross talk between the protein kinase A and mitogen-activated protein kinase signaling pathways. Molecular Endocrinology, 18(2), 291-302.
9. Dalessandri, K. M., Firestone, G. L., Fitch, M. D., Bradlow, H. L., & Bjeldanes, L. F. (2004). Pilot study: Effect of 3,3’-diindolylmethane supplements on urinary hormone metabolites in postmenopausal women with a history of early-stage breast cancer. Nutrition and Cancer, 50(2), 161-167.
10. Bradlow, H. L., Telang, N. T., Sepkovic, D. W., & Osborne, M. P. (1996). 2-hydroxyestrone: the ‘good’ estrogen. Journal of Endocrinology, 150(S2), 59-65
2. Zeligs, M. A., Fulfs, J. C., Peterson, R., Wilson, S. M., McIntyre, L., Sepkovic, D. W., & Bradlow, H. L. (2003). In vivo, uterine-protective activity of absorption-enhanced diindolylmethane: Animal and preliminary human use in combination with Tamoxi-fen. Proceedings of the American Association of Cancer Research, 44, 1268.
3. Zeligs, M. A., Sepkovic, D. W., Manrique, C., Macsalka, M., Williams, D. E., & Bradlow, H. L. (2002). Absorption-enhanced 3,3’-diindolylmethane: Human use in HPV-related, benign and pre-cancerous conditions. Proceedings of the American Association of Cancer Research, 43, 3198.
4. Teas, J., Cunningham, J. E., Fowke, J. H., Nitcheva, D., Kanwat, C. P., Boulware, R. J., Sepkovic, D. W., Hurley, T. G., & Hebert, J. R. (2005). Urinary estrogen metabolites, prostate specific antigen, and body mass index among African-American men in South Carolina. Cancer Detection and Prevention, 29(6), 494-500.
5. Michnovicz, J. J., Adlercreutz, H., & Bradlow, H. L. (1997). Changes in levels of urinary estrogen metabolites after oral indole-3-carbinol treatment in humans. Journal of the National Cancer Institute, 89(10), 718-723.
6. Chen, I., McDougal, A., Wang, F., & Safe, S. (1998). Aryl hydrocarbon receptor-mediated antiestrogenic and antitumorigenic activity of diindolylmethane. Carcinogenesis, 19(9), 1631-1639.
7. Aggarwal, B. B., & Ichikawa, H. (2005). Molecular targets and anticancer potential of indole-3-carbinol and its derivatives. Cell Cycle, 4(9), 1201-1215.
8. Leong, H., Riby, J. E., Firestone, G. L., & Bjeldanes, L. F. (2004). Potent ligand-independent estrogen receptor activation by 3,3’-diindolylmethane is mediated by cross talk between the protein kinase A and mitogen-activated protein kinase signaling pathways. Molecular Endocrinology, 18(2), 291-302.
9. Dalessandri, K. M., Firestone, G. L., Fitch, M. D., Bradlow, H. L., & Bjeldanes, L. F. (2004). Pilot study: Effect of 3,3’-diindolylmethane supplements on urinary hormone metabolites in postmenopausal women with a history of early-stage breast cancer. Nutrition and Cancer, 50(2), 161-167.
10. Bradlow, H. L., Telang, N. T., Sepkovic, D. W., & Osborne, M. P. (1996). 2-hydroxyestrone: the ‘good’ estrogen. Journal of Endocrinology, 150(S2), 59-65